Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 8Astrocytoma 3Oligodendroglioma 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hodgkin Disease 2Glioma 2Brain Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gliosarcoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 65Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 30Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Rituximab 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Carmustine × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT00761280 2014-11-14

SAPPHIRE

Isarna Therapeutics GmbH

Phase 3 Terminated
27 enrolled 28 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡